| ²é¿´: 4884 | »Ø¸´: 15 | ||||
kuaile569ľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
¡¾×ªÌû¡¿ÃÀ¹ú×Ô1995µ½2008ÄêÉÏÊеĿ¹°©ÐÂÒ© ÒÑÓÐ3È˲ÎÓë
|
|
ÃÀ¹ú×Ô1995µ½2008ÄêÉÏÊеĿ¹°©ÐÂÒ© Drugs Approved in 2008 ¡¡ Treanda (bendamustine hydrochloride) ; ÖÎÁÆÂýÐÔÁܰÍϸ°ûÐÔ°×Ѫ²¡; Cephalon; Approved 2008 3Ô Drugs Approved in 2007 Hycamtin (topotecan) ; ÖÎÁÆÐ¡Ï¸°û·Î°© ÍíÆÚ×Ó ¹¬¾±°© Âѳ²°© ,GlaxoSmithKline; Approved October 2007 Ixempra (ixabepilone) ; ͨ¹ýFDAµÄÅú×¼Óà ×÷Ò»ÏßÒ©ÎïÖÎÁÆÍíÆÚÈéÏÙ°©; Bristol Myers Squibb; October 2007 Tykerb (lapatinib) ; ÈéÏÙ°©ÍíÆÚÐÂÒ© Tykerb,ÊǸðÀ¼ËØÊ·¿Ë¹«Ë¾ÑÐÖÆµÄ¡£ ÁÙ´²ÊÔÑéÏÔʾ,¶ÔÓÚÄÇЩÒѶÔÂÞÊϵĺÕÈüÍ¡(Herceptin)²úÉúÄÍÒ©ÐÔµÄHER2ÐÍÈé°©»¼Õß,ÕâÖÖÐÂÒ©ÓкܺõÄÁÙ´²Ð§¹û¡£ Torisel (temsirolimus) ; ÍíÆÚÉö°©×îÐÂÒ©Î ÊÇΨһÉÏÊеÄÌØÒìÐÔÒÖÖÆmTOR¼¤Ã¸µÄÒ©Îï,mTOR¼¤Ã¸Êǵ÷½Úϸ°ûÔöÖµ¡¢Éú³¤ºÍϸ°û´æ»îÖØÒªµÄµ°°×ÖÊ¡£Äܹ»ÓÐЧÒÖÖÆºÍµ÷½Úµ°°×ϸ°ûÔöÖ³¡¢Ï¸°ûÉú³¤ºÍϸ°û ´æ»îÂÊ,ÊÇĿǰµÚÒ»¼ÁÓÃÓÚÖÎÁư©Ö¢µÄ×¢Éä¼Á¡£ Tasigna (nilotinib hydrochloride monohydrate) ; ÖÎÁÆÂýÐÔ¹ÇËèÐÔ°×Ѫ²¡µÄÐÂÒ© Novartis; 2007Äê10 ÔÂÅú×¼ÉÏÊÐ vista (raloxifene hydrochloride) ; ÖÎÁƺÍÔ¤·À¹ÇÖÊÊèËÉÒÔ¼°¼õÉÙ¾ø¾ÆÚ¸¾Å®ÈéÏÙ°©µÄ·¢Éú£»Eli Lilly; 07Äê9 ÔÂÉÏÊС£ Drugs Approved in 2006 Sutent (sunitinib) ; ÖÎÁÆÉöϸ°ûÖ×ÁöºÍ賦µÀ¼äÖÊÖ×ÁöÐÂÒ©¡£PfizerÉú²ú; 2006Äê1ÔÂÅú×¼ÉÏÊС£ Sprycel(dasatinib) ; ÓÃÓÚÖÎÁÆÁ½ÖÖеÄÊÊÓ¦Ö¢£º¶ÔÒÁÂíÌæÄáµÈÒ»ÏßÒ©ÎﻯÁƲ»Ãô¸ÐµÄ¸÷ÆÚÂýÐÔÁ£Ï¸°û°×Ѫ²¡(CML)£¬ÒÔ¼°¶ÔÆäËûÁÆ·¨ÎÞЧ»ò²»ÄÜÄÍÊܵÄPhȾɫÌåÑôÐԵļ±ÐÔÁܰÍϸ°û°×Ѫ ²¡(ALL)¡£ Vectibix (panitumumab) ÐÖúÖÎÁÆ´ó³¦Ö±³¦°©ÒÑÀ©É¢µ½ÆäËü²¿Î»µÄ»¼Õß ¡£ ¶ÔÖ×ÁöÓмõ »º¶ñ»¯µÄЧÓà (ÔÚijЩ²¡ÀýÉõÖÁÄÜËõСÖ×Áö) Drugs Approved in 2005 Arranon (nelarabine) ; ÖÎÁƼ±ÐÔ³ÉÁܰÍϸ°ûÐÔ°×Ѫ²¡ Tϸ°ûÁܰÍÁöÐÂÒ© GlaxoSmithKlineÉú²ú; 05Äê10 Ô¡£ Nexavar (sorafenib) ; È«ÇòÊ׸ö¿Ú·þ¶à¼¤Ã¸ÒÖÖÆ¼Á£¬ÖÎÁÆÍíÆÚÉöϸ°û°©µÄÒ©ÎBayer/OnyxÉú²ú; 05Äê12 Ô¡£ Revlimid (lenalidomide) ; ÖÎÁÆÇáÖжÈ-1-risk ¹ÇËèÔöÉúÒì³£×ÛºÏÕ÷ºÏ; CelgeneÉú²ú; 2005Äê12ÔÂÅú×¼ÉÏÊС£ Abraxane ( PACLITAXEL PROTEIN-BOUND ) ; ÃÀ¹úÖÆÒ©»ï°é¹«Ë¾(American Pharmaceutical Partners,APP)ºÍÃÀ¹úÉúÎï¿ÆÑ§(American BioScience)½üÈÕÐû²¼£¬ÃÀ¹úFDAÅú×¼ÁËAbraxaneÓÃÓÚÖÎÁÆ×ªÒÆÐÔÈéÏÙ°©µÄÐÂÒ©ÉêÇë¡£Á½¼Ò¹«Ë¾ÀûÓÃËûÃǵÄרÀûÄÉÃ×¼¼Êõ,°ÑAbraxaneµÄ»îÐԳɷÖ×Ïɼ´¼(Paclitaxel)ºÍÖ»Óкìϸ°û1%´óСµÄÄÉÃ×°×µ°°×¿ÅÁ£½áºÏÔÚÒ»Æð£¬´Ó¶ø±ÜÃâÁ˸÷ÖÖÈܽâ¿ÉÄÜ¡£AbraxaneÊǵÚÒ»·ÇÈܽâÄÉÃ×°×µ°°×½áºÏ»¯ÁÆÒ©Î¿ÉÒÔÓÐЧµÄÀûÓð׵°°×ÊÜÌåÄÚÔÚ;¾¶´«ÊäÒ©Îïͨ¹ýÖ×ÁöÐÂÉúѪ¹ÜÄÚÆ¤Ï¸°û±Ú¡£Óëµ¥´¿×Ïɼ´¼Ïà±È£¬Æä×÷ÓÃʱ¼ä³¤£¬¸±×÷ÓÃС¡£ Drugs Approved in 2004 Alimta (pemetrexed for injection) ; ÖÎÁƶñÐÔÐØÄ¤¼äƤÁö£¬li Lilly Éú²ú; 2004Äê¶þÔÂÅú×¼ÉÏÊÐ Avastin (bevacizumab) ; ÖÎÁƶñÐÔÖ±³¦°©; GenentechÉú²ú; 2004Äê2ÔÂÅú×¼ÉÏÊÐ Erbitux (cetuximab) ; ÖÎÁÆEGFR-±íÏֵĶñÐԽ᳦ֱ³¦°©; Imclone / Bristol-Myers SquibbÉú²ú; 2004Äê¶þÔÂÉÏÊÐ Sensipar (cinacalcet) ; ÖÎÁƼ̷¢ÐÔ¼××´ÅÔÏÙ¹¦ÄÜ¿¹½ø(¼××´ÅÔÏÙ°©)ÒýÆðµÄ¸ßѪ¸Æ; AmgenÉú²ú; 2004ÄêÈýÔÂÉÏÊÐ Clolar (clofarabine) ; ÓÃÓÚÖÎÁÆÐ¡¶ù¼±ÐÔÁܰÍϸ°ûÐÔ°×Ѫ²¡; Genzyme; Éú²ú; 2004Äê12ÔÂÅú×¼ÉÏÊÐ Tarceva (erlotinib, OSI 774) ; ÓÃÓÚÖÎÁƶñÐÔ£¬ÄÑÖÎÐÔ·ÇСϸ°û·Î°©; Genentech, OSI PharmaceuticalsÉú²ú; 04Äê11 Drugs Approved in 2003 Emend (aprepitant) ; ÖÎÁÆ»¯ÁƲ¡È˵ĶñÐÄ£¬Å»ÍÂ; MerckÉú²ú; 2003Äê3ÔÂÅú×¼ÉÏÊÐ Iressa (gefitinib) ; ÖÎÁÆ·ÇСϸ°û·Î°©µÄÐÂÒ©£¬AstraZenecaÉú²ú; 2003Äê5ÔÂÅú×¼ÉÏÊÐ Aloxi (palonosetron) ; Ô¤·ÀÖ×Áö»¯ÁƲ¡È˵ĶñÐÄ£¬Å»Í ; MGI Pharma / Helsinn HealthcareÑз¢Éú²ú; 2003Äê8Ô UroXatral (alfuzosin HCl extended-release tablets);ÖÎÁÆÁ¼ÐÔǰÁÐÏÙÔöÉúµÄ¸÷ÖÖÖ¢×´; Sanofi-SynthelaboÉú²ú; 2003Äê6ÔÂÅú×¼ÉÏÊÐ Velcade (bortezomib) ; ÖÎÁÆÖÁÉÙ½ÓÊܹý¶þÖÖÒÔÉÏÁÆ·¨µÄ¶à·¢ÐÔ¹ÇËèÁöµÃ²¡ÈË; Millennium PharmaceuticalsÉú²ú; 2003Äê5ÔÂÅú×¼ÉÏÊÐ exxar ; ÖÎÁÆCD20ÑôÐÔ£¬µÄСÄÒÐÔ·Ç»ô½Ü½ðÊÏÁܰÍÁö»¯ÁƸ´·¢µÄ²¡ÈË; CorixaÉú²ú; 2003Äê6ÔÂÅú×¼ÉÏÊÐ Drugs Approved in 2002 Eligard (leuprolide acetate) ; ǰÁÐÏÙ°©¿¹°©ÐÂÁÆ·¨ ÓÃÓÚǰÁÐÏÙ°©µÄ»º½âÖÎÁÆ ; Atrix Laboratories; 2002Äê 1 ÔÂÅú×¼ ÉÏÊÐ Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); ÓÃÓڽ᳦ºÍÖ±³¦°©Ö¢µÄÖÎÁÆ ; Sanofi-SynthelaboÉú²ú; 2002Äê8ÔÂÅú×¼ ÉÏÊÐ Faslodex (fulvestrant) ; ÖÎÁƼ¤ËØÊÜÌåÑôÐԵĴúÐ»×ªÒÆÐÔÈéÏÙ°©; AstraZenecaÉú²ú; 02Äê4ÔÂÅú Gleevec ; ÖÎÁÆÑª°© ( ÂýÐÔ¹ÇËèÐÔ°×Ѫ²¡) chronic myelogenous leukemia (CML) ·Ç³£ÓÐЧ£¬²¢¶ÔÖÎÁÆÎ¸³¦»ùµ×ϸ°û°© (gastrointestinal stromal tumor) (GIST) ¡¢Ç°ÁÐÏÙ°©µÈÒàÓÐÃ÷ÏÔЧ¹û ; ÓÉ Novartis ¿ª·¢Éú²ú ; 2002 Äê 2 ÔÂÅú×¼ 賦°©ÐÂÊÊÓ¦Ö¢ Neulasta ; ½µµÍÓÉÓÚ»¯ÁÆÒýÆðµÄÖÐÐÔ°×ϸ°û¼õÉÙÖ¢¶øµ¼ÖµĸÐȾ»ú»á Amgen; 2002Äê1ÔÂÅú×¼ ÉÏÊÐ SecreFlo (secretin) ; ÓÃÓÚÒÈÏÙ¹¦ÄÜÕï¶ÏºÍÖÎÁÆÎ¸ÃÚËØÖ×Áö; Repligen; 2002Äê4ÔÂÅú×¼ ÉÏÊÐ Zevalin (ibritumomab tiuxetan) ; ÖÎÁÆ·Ç»ô½Ü½ðÊÏÁܰÍÈâÁö ; IDEC Pharmaceuticals; 2002 Äê 2 ÔÂÅú×¼ ÉÏÊÐ Zometa (zoledronic acid) ; ÖÎÁƶ෢ÐÔ¹ÇËèÁö ʵÌåÖ×Áöµ¼Ö嵀 ¹Ç»µËÀ ; Novartis; 2002 Äê 2 ÔÂÅú×¼ ÉÏÊÐ Drugs Approved in 2001 Campath ; ×¢ÉäÓÃÒ©ÖÎÁÆB-ϸ°ûÂýÐÔÁܰÍÐÔ°×Ѫ²¡; ÓÉBerlex Laboratories ¿ª·¢Éú²ú ; 2001Äê5ÔÂÅú×¼ÉÏÊÐ Femara (letrozole) Ƭ¼Á; Í£¾ºó¸¾Å®î¾»¼×ªÒÆÐÔÈé°©µÄµÚÒ»ÏßÖÎÁÆÒ©Îï; ÓÉNovartis ¿ª·¢Éú²ú ; 01Äê1Ô Gleevec ; ÖÎÁÆÑª°© ( ÂýÐÔ¹ÇËèÐÔ°×Ѫ²¡) chronic myelogenous leukemia (CML) ·Ç³£ÓÐЧ£¬²¢¶ÔÖÎÁÆÎ¸³¦»ùµ×ϸ°û°© (gastrointestinal stromal tumor) (GIST) ¡¢Ç°ÁÐÏÙ°©µÈÒàÓÐÃ÷ÏÔЧ¹û ; ÓÉNovartis ¿ª·¢Éú²ú ; 2001Äê5ÔÂÅú×¼ÉÏÊÐ Kytril (granisetron) Solution ; »¯ÁƲ¡È˵ĶñÐÄ£¬Å»ÍÂ; Hoffmann-La RocheÉú²ú; 2001Äê6ÔÂÅú×¼ÉÏÊÐ Trelstar LA ; ¼¡Èâ×¢ÉäÕë¼Á£¬ÀÏÄêǰÁÐÏÙ°©Ö¢ÖÎÁÆ; Debiopharm S.A.;Éú²ú; 2001Äê6ÔÂÅú×¼ÉÏÊÐ Xeloda ; Ö±³¦½á³¦°©Ö¢¿Ú·þ»¯ÁÆÒ©; Hoffman-La RocheÉú²ú; 2001Äê5ÔÂÅú×¼ÉÏÊÐ Zometa (zoledronic acid) ; ÓÃÓÚ¶ñÐÔ¸ßѪ¸ÆÖ¢µÄÖÎÁÆFor the treatment of hypercalcemia of malignancy; NovartisÉú²ú; 2001Äê8ÔÂÅú×¼ÉÏÊÐ Drugs Approved in 2000 Mylotarg ( gemtuzumab ozogamicin) ; CD33 ÑôÐԵļ±ÐÔËèÐÔ°×Ѫ²¡(AML); WyethÉú²ú; 2000Äê5ÔÂÅú×¼ÉÏÊÐ Trelstar Depot (Injectable Triptorelin Pamoate) ; ½øÐÐÐÔǰÁÐÏÙ°©¹ÃÏ¢ÁÆ·¨ ; Debio Rechereche Pharmaceutique SA (c/o Target Research Associates)Éú²ú; 2000Äê6ÔÂÅú×¼ÉÏÊÐ Trisenox (arsenic trioxide) ; Ò»ÖÖº¬ÉéµÄÒ©ÎҲ¾ÍÊÇÎÒÃÇË×³Æ µÄÅøËª£¬¿ÉÒÔÓÃÀ´ÖÎÁÆÒ»¸öÖÂÃüÐԵĺ±¼û¼²²¡©¤¼±ÐÔǰ¹ÇËæÏ¸°ûÐÔ°×Ѫ²¡ £¬ÕâÊÇÃÀ¹ú½ü°ÙÄêÀ´Ê״κË×¼µÄÉéÁÆ·¨¡£ÊÊÓ¦³ÉÄ껼Õߵĸ´·¢/Íç¹ÌÐͼ±ÐÔÔçÓ×Á£Ï¸°û°×Ѫ²¡ÖÎÁÆ(APL)Cell Therapeutics Éú²ú; 2000Äê9ÔÂÅú×¼ÉÏÊÐ Viadur (leuprolide acetate implant) ;ÓÃÓÚ ½øÐÐÐÔǰÁÐÏÙ°©ÌÛÍ´»º½â ; ALZA CorporationÉú²ú; 2000Äê3ÔÂÅú×¼ÉÏÊÐ Drugs Approved in 1999 Aromasin Tablets; Exemestane Tablets, 25 mg; Èé°©»¼Õ߸ķþ AROMASIN ¸üÓпÉÄܱ£³Ö°©Ö¢²»¸´·¢ Pharmacia & UpjohnÉú²ú; 1999Äê10ÔÂÅú×¼ÉÏÊÐ Busulflex ; ºÏ²¢ÓÃÓÚ°×Ѫ²¡µÄ×ÛºÏÖÎÁÆ ; Orphan Medical, Inc.Éú²ú; 1999Äê2ÔÂÅú×¼ÉÏÊÐ Doxil (doxorubicin HCl liposome injection); ÖÎÁÆÍç¹ÌÐÔÂѳ²°©¡£ÊÊÓÃÓÚÄÇÐ©Ôø¾Óùýµ±½ñÒ»Á÷µÄ»¯ÁÆ·½·¨Ò½ÖιýµÄÍç¹ÌÐÔÂѳ²°©»¼Õß¡£Íç¹ÌÐÔÂѳ²°©±»¶¨ÒåΪ£ºÔÚÖÎÁƹý³ÌÖлòÍê³ÉÖÎÁƺó6¸öÔÂÀﲡÇé²»¶Ï¶ñ»¯µÄ¼²²¡¡£Treatment for ovarian cancer that is refractory to other first-line therapies; Alza Corp.Éú²ú; 1999Äê6ÔÂÅú×¼ÉÏÊÐ; Ellence ; epirubicin hydrochloride; ¿É ÖÎ ÁÆ Ôç ÆÚ ÓÉ Èé °© À© É¢ ÖÁ ÁÜ °Í ½á °© Ö× µÄ Å® ÐÔPharmacia & UpjohnÉú²ú; 1999Äê9ÔÂÅú×¼ÉÏÊÐ; Ethyol (amifostine); ÖÎÁÆÖ×Áö·ÅÁƲ¡È˵ĿÚÇ»¸ÉÔïÖ¢(dry mouth); U.S. Bioscience and Alza Corp.Éú²ú; 99Äê6Ô Temodar ; ÖÎÁÆÄÑÖÎÐÔÍËÐÐÐÔÐÇ״ϸ°ûÁö; Schering-PloughÉú²ú; 1999Äê8ÔÂÅú×¼ÉÏÊÐ; UVADEX Sterile Solution; ÖÎÁÆµÄÆ¤·ôTϸ°ûÁܰÍÁö(Cutaneous T cell lymphoma, CTCL)µÄƤ·ô¸Ä±ä; Therakos, Inc.Éú²ú; 1999Äê2ÔÂÅú×¼ÉÏÊÐ; Zofran ODT; Ô¤·ÀÖ×Áö»¯ÁƺͷÅÁƲ¡È˵ĶñÐÄ£¬Å»ÍÂ; Glaxo Wellcome Inc.Éú²ú; 1999Äê1ÔÂÅú×¼ÉÏÊÐ; Drugs Approved in 1998 Actiq ; ÖÎÁư©Ö¢ÌÛÍ´ Pain; Anesta CorporationÉú²ú; 1998Äê11ÔÂÅú×¼ÉÏÊÐ; Anzemet ;ÖÎÁÆÔ¤·ÀÖ×Áö»¯ÁƺÍÊÖÊõ²¡È˵ĶñÐÄ£¬Å»ÍÂ; 1998Äê2ÔÂÅú×¼ÉÏÊÐ Camptosar ; ÖÎÁÆÖ±³¦½á³¦°©Ö¢; Pharmacia & UpjohnÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ Gemzar ; ÖÎÁƷΰ©; Eli LillyÉú²ú; 1998Äê8ÔÂÅú×¼ÉÏÊÐ Herceptin ; ÖÎÁƶñÐÔÈé·¿°©; GenentechÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ Neupogen ; ÖÎÁÆÖ×Áö²¡ÈË»¯Áƺó°×ϸ°û»Ö¸´»ºÂý; AmgenÉú²ú; 1998Äê4ÔÂÅú×¼ÉÏÊÐ Nolvadex ; ÖÎÁÆÈéÏÙ°©; Zeneca PharmaceuticalsÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ Photofrin ; ÖÎÁÆÔçÆÚ·ÇСϸ°û·Î°© microinvasive endobronchial non-small cell lung cancer; QLT TherapeuticsÉú²ú; 1998Äê1ÔÂÅú×¼ÉÏÊÐ Proleukin ; ÖÎÁÆ´úлÐÔºÚÉ«ËØÁö Chiron CorporationÉú²ú; 1998Äê1ÔÂÅú×¼ÉÏÊÐ Sclerosol Intrapleural Aerosol ; ÖÎÁƶñÐÔÐØÇ»»ýÒº; Bryan CorporationÉú²ú; 1998Äê1ÔÂÅú×¼ÉÏÊÐ Valstar ; ÖÎÁưòë×°©; Anthra PharmaceuticalsÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ Xeloda ; ÖÎÁƽøÐÐÐÔÈé·¿°©Áö; Hoffmann LaRocheÉú²ú; 1998Äê4ÔÂÅú×¼ÉÏÊÐ Zofran ; ÖÎÁƳÉÄêÈËÊÖÊõºóµÄ¶ñÐÄ£¬Å»ÍÂ; Glaxo WellcomeÉú²ú; 1998Äê4ÔÂÅú×¼ÉÏÊÐ Drugs Approved in 1997 Anzemet ; Treatment for emesis; Hoechst Marion Roussel; Approved September 1997 Bromfenac ; Management of acute pain; Duract, Wyeth-Ayerst; Approved July 1997 Femara ; Treatment for breast cancer; Novartis; Approved July 1997 Gliadel Wafer (polifeprosan 20 with carmustine implant) ; Treatment for brain cancer; Rhone-Poulenc Rorer, Inc. and Guilford Pharmaceuticals Inc.; Approved February 1997 Intron A ; Treatment for non-Hodgkin's lymphoma; Schering-Plough Corp.; Approved December 1997 Kytril ; Prevention of nausea and vomiting associated with chemotherapy; SmithKline Beecham; 1997£¨11£© Lupron Depot ; Treatment for prostate cancer; Tap Holdings; Approved July 1997 Miraluma test ; Test for breast cancer; DuPont Pharma Radiopharmaceuticals; Approved May 1997 Neumega ; Treatment for thrombocytopenia; Genetics Institute; Approved November 1997 Quadramet (Samarium Sm 153 Lexidronam Injection) ; Treatment for pain associated with bone cancer; DuPont Merck Pharmaceutical Company; Approved March 1997 Rituxan ; Treatment for non-hodgkin's lymphoma; Idec Pharmaceuticals; Genentech Inc.; Approved 11ÔÂ1997 Taxol ; Treatment for AIDS-related Kaposi's Sarcoma; Bristol-Myers Squibb; Approved August 1997 Drugs Approved in 1996 Anexsia ; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996 Aredia (pamidronate disodium for injection) ; Treatment for osteolytic bone metastases of breast cancer; Chiron Therapeutics, Ciba Pharmaceuticals; Approved August 1996 Arimidex (anastrozole) ; Treatment for advanced breast cancer in postmenopausal women; Zeneca; Approved 1ÔÂ1996 Camptosar Injection ; Treatment for metastatic colorectal cancer; Pharmacia & Upjohn; Approved June 1996 CEA-Scan; Diagnostic imaging product for colorectal cancer; Immunomedics; Approved April 1996 Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) ; Treatment of meningeal leukemia or lymphocytic lymphoma; Orphan Medical, Inc.; Approved October 1996 Eulexin (flutamide) ; Treatment for prostate cancer; Schering-Plough Corporation; Approved June 1996 Feridex I.V. ; Contrast agent for magnetic resonance imaging of liver lesions; Advanced Magnetics; 1996Äê 2Ô GastroMARK ; Contrast agent for magnetic resonance imaging of the gastrointestinal tract; Advanced Magnetics; Approved May 1996 Gemzar (Gemcitabine HCl) ; Treatment for pancreatic cancer; Eli Lilly; Approved May 1996 Hycamtin (topotecan hydrochloride) ; Treatment for metastatic ovarian cancer; SmithKline Beecham; Approved May 1996 Kadian ; Treatment for chronic moderate to severe pain; Purepac Pharmaceutical; Approved July 1996 Leukine (sargramostim) ; Treatment for the replenishment of white blood cells; Immunex Corporation; 1996£¨11£© Lupron Depot (leuprolide acetate for depot suspension) ; Treatment for advanced prostate cancer; Abbott Laboratories; 1996£¨01£© Photodynamic Therapy; Photodynamic therapy device for the treatment of esophageal cancer; Sanofi Winthrop, QLT PhotoTherapeutics; Approved January, 1996 Taxotere (Docetaxel) ; Treatment for locally advanced or metastatic breast cancer; Rhone Poulenc Rorer; 1996£¨05£© UltraJect ; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996 Visipaque (iodixanol) ; Diagnostic contrast agent; Nycomed; Approved April 1996 Zoladex (10.8 mg goserelin acetate implant) ; Treatment for advanced prostate cancer; Zeneca; Approved January 1996 Drugs Approved in 1995 Ethyol (amifostine) ; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer; Alza Pharmaceuticals, U.S. Bioscience; Approved December 8, 1995 Intron A (Interferon alfa-2b, recombinant) ; An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma; Schering-Plough; Approved December 1995 Leukine (sargramostim) ; Treatment for mobilizing peripheral blood progenitor cells for use after transplantation.; Immunex Corp.; Approved on November 24, 1995 Self-examination breast pad; Self-examination breast pad; Inventive Products Inc.; Approved on December 1995 |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
»¯Ñ§ºÏ³É |
» ²ÂÄãϲ»¶
¶þÒÒÏ©»ùí¿µÄºÏ³É·¾¶
ÒѾÓÐ4È˻ظ´
ÇóÒ»Öê[b]ÇóýMTAP(human)µÄHCT-116(È˽᳦°©Ï¸°û)/b]ϸ°û
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ135È˻ظ´
Õâ¸ö×Ô·¢¼ÓÑõ·´Ó¦µÄ»úÀíÊÇʲô£¿
ÒѾÓÐ7È˻ظ´
ÇóÖú£¡ÇóÃÀ¹úʳƷ»¯Ñ§Ò©µäÄÚÈÝ£ºFCC13¡¾µÍ¾Û¹ûÌÇרÂÛ¡¿
ÒѾÓÐ0È˻ظ´
¡¾2027²©Ê¿ÉêÇë¡¿ÄÉÃ×Ò©ÎïµÝËÍ·½Ïò
ÒѾÓÐ5È˻ظ´
ÏûºÄ΢Á¿API£¬±ã¿ÉÔ¤²âÔçÆÚÑз¢½×¶ÎµÄHME¹¤ÒÕ¿ÉÐÐÐÔ
ÒѾÓÐ0È˻ظ´
·´Ó¦ÒºÖб½ôû³ýÈ¥
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
°¢Ë¹Àû¿µºÍ¼Ç»ÆÆÒÒ½Ò©ÁªºÏ¿ª·¢¿¹°©ÐÂÒ©
ÒѾÓÐ28È˻ظ´
»ÔÈðÖÕÓÚ»ñµÃ¿¹°©ÐÂÒ©Åú×¼ÉÏÊÐ
ÒѾÓÐ14È˻ظ´
ÎҾͲ»ÐÅÕâôºÃµÄÌû×Ó ÔÚÕâÀï»ð²»ÁË ÖйúÑз¢¡°¶öËÀ¡±Ö×Áö¿¹°©ÐÂÒ© Íê³É¶þÆÚÁÙ´²
ÒѾÓÐ23È˻ظ´
![]() |
2Â¥2009-08-27 10:10:56
| лл·ÖÏí£¡ |
3Â¥2009-08-31 15:37:48
| лл·ÖÏí |
4Â¥2009-10-12 16:24:07
| лл·ÖÏí |
5Â¥2009-10-12 16:54:50
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
6Â¥2009-10-29 11:25:15
llyz0825
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 5292.5
- É¢½ð: 10
- ºì»¨: 2
- Ìû×Ó: 1367
- ÔÚÏß: 37.5Сʱ
- ³æºÅ: 781962
- ×¢²á: 2009-05-29
- רҵ: Ò©Îﻯѧ
7Â¥2009-10-30 08:21:02
akram
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 329.3
- É¢½ð: 32
- Ìû×Ó: 126
- ÔÚÏß: 30.3Сʱ
- ³æºÅ: 892002
- ×¢²á: 2009-11-03
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
8Â¥2009-11-07 20:31:43
akram
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 329.3
- É¢½ð: 32
- Ìû×Ó: 126
- ÔÚÏß: 30.3Сʱ
- ³æºÅ: 892002
- ×¢²á: 2009-11-03
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
9Â¥2009-11-07 20:32:06
akram
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 329.3
- É¢½ð: 32
- Ìû×Ó: 126
- ÔÚÏß: 30.3Сʱ
- ³æºÅ: 892002
- ×¢²á: 2009-11-03
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
10Â¥2009-11-07 20:32:47









»Ø¸´´ËÂ¥


28